Company Performance Metrics
Parley Neurotech, Inc. is a clinical-stage biotechnology company spun out of the University of Colorado Anschutz Medical Campus that targets the neurological root cause of age-related central auditory processing disorder (CAPD), colloquially known as "Cocktail Party Syndrome." Rather than simply amplifying external volume like a
traditional hearing aid, the company’s proprietary Localized Oligodendrocyte Optimization Therapy (LOOT) pairs an oral, blood-brain-barrier-crossing remyelinating drug (clemastine fumarate) with targeted, engineered acoustic sound therapy over a 30-day period. Backed by 30 years of neuroscience research out of the university's Klug Laboratory, this dual-action therapeutic approach works synergistically to stimulate precursor cells and repair the specific, demyelinated auditory brain circuits responsible for speech-in-noise processing deficits.
